Sun Hao, Sun Ting, Ma Bing, Yang Bo-wen, Zhang Yao, Huang Dong-hui, Shi Jing-pu
Department of Clinical Epidemiology and Evidence-based Medicine, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Institute of Cardiovascular Diseases, First Affiliated Hospital, China Medical University, Shenyang 110001, China; Center of Evidence Based Medicine, Liaoning Province & China Medical University, Shenyang 110001, China.
Peptides. 2015 Jul;69:9-18. doi: 10.1016/j.peptides.2015.03.023. Epub 2015 Apr 4.
Measurement of the biomarker copeptin may help identify disease severity and risk of mortality for a various diseases. This study sought to determine the relationship between copeptin and all-cause mortality of patients with cardio-cerebrovascular disease.
Database of Medline and Web of Science were searched for studies with data involving the baseline copeptin levels and subsequent all-cause mortality outcomes. The pooled HRs of all-cause mortality were calculated and presented with 95%CIs. Subgroup analysis and sensitivity analysis were conducted to explore the possible sources of heterogeneity.
Data from 14,395 participants were derived from 28 prospective studies. Higher copeptin significantly increased the risk of all-cause mortality (per unit copeptin: HR=1.020, 95%CI=1.004-1.036; log unit copeptin: HR=2.884, 95%CI=1.844-4.512; categorical copeptin: HR=3.371, 95%CI=2.077-5.472). Subgroup analysis indicated that the risk of all-cause death was higher in cerebrovascular patients (per unit copeptin: HR=2.537, 95%CI=0.956-6.731; log unit copeptin: HR=3.419, 95%CI=2.391-4.888) than cardiovascular patients (per unit copeptin: HR=1.011, 95%CI=1.002-1.020; log unit copeptin: HR=2.009, 95%CI=1.119-3.608).
Copeptin is associated with all-cause mortality of patients with cardiovascular and cerebrovascular disease. Our study suggests that copeptin seems to be a promising novel biomarker for prediction of mortality in cardio-cerebrovascular patients, especially for cerebrovascular patients.
